Streetbeat News

NAYA

NAYA Biosciences, Inc.

http://www.nayabiosciences.com

Industry

Medical - Devices

INVO Bioscience is a medical device company providing devices and products for infertility diagnosis. Its flagship product is INVOcell, a reproductive technology that allows fertilization and early embryo development to take place within the woman’s body.

Open

2.34

Mkt cap

1.8M

Volume

75K

High

2.74

P/E Ratio

-0.19

52-wk high

42.00

Low

2.31

Div yield

N/A

52-wk low

1.94

NAYA Biosciences, Inc. (NASDAQ: NAYA) will implement a 1-for-12 reverse stock split effective March 18, 2025. The company's stock will trade on a post-split basis under the same symbol 'NAYA'.

Portfolio Pulse from

March 13, 2025 | 8:45 pm

NAYA Biosciences supports a recent executive order aimed at improving access to fertility treatment. The company anticipates a positive impact on its fertility operations and FDA-cleared INVOcell technology.

Portfolio Pulse from

February 25, 2025 | 1:15 pm

NAYA Biosciences will present insights on its GPC3-targeting NK engager bispecific antibody, NY-303, at the 2024 SITC meeting. The presentation will support upcoming clinical trials and demonstrate the antibody's potential to enhance immunotherapy effectiveness.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 1:01 pm

NAYA Biosciences has announced the initiation of a Phase 1/2a clinical trial for its GPC3-targeted NK Engager bispecific antibody, NY-303, in patients with hepatocellular carcinoma. The trial has received regulatory approval in Israel and will be conducted in up to 7 academic centers.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:17 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.